Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Susceptibility of Mice to Trypanosoma evansi Treated with Human Plasma Containing Different Concentrations of Apolipoprotein L-1

  • Da Silva, Aleksandro S. (Department of Microbiology and Parasitology, Universidade Federal de Santa Maria) ;
  • Fanfa, Vinicius R. (Department of Microbiology and Parasitology, Universidade Federal de Santa Maria) ;
  • Otto, Mateus A. (Department of Microbiology and Parasitology, Universidade Federal de Santa Maria) ;
  • Gressler, Lucas T. (Department of Microbiology and Parasitology, Universidade Federal de Santa Maria) ;
  • Tavares, Kaio C.S. (Laboratory of Hemoparasites and Vectors Biochemistry, Universidade do Estado de Santa Catarina) ;
  • Lazarotto, Cicera R. (Laboratory of Hemoparasites and Vectors Biochemistry, Universidade do Estado de Santa Catarina) ;
  • Tonin, Alexandre A. (Department of Microbiology and Parasitology, Universidade Federal de Santa Maria) ;
  • Miletti, Luiz C. (Laboratory of Hemoparasites and Vectors Biochemistry, Universidade do Estado de Santa Catarina) ;
  • Duarte, Marta M.M.F. (Lutheran University of Brazil-ULBRA) ;
  • Monteiro, Silvia G. (Laboratory of Hemoparasites and Vectors Biochemistry, Universidade do Estado de Santa Catarina)
  • Received : 2011.09.08
  • Accepted : 2011.10.02
  • Published : 2011.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study was to test the susceptibility of mice to Trypanosoma evansi treated with human plasma containing different concentrations of apolipoprotein L-1 (APOL1). For this experiment, a strain of T. evansi and human plasma (plasmas 1, 2, and 3) from 3 adult males clinically healthy were used. In vivo test used 50 mice divided in 5 groups (A to E) with 10 animals in each group. Animals of groups B to E were infected, and then treated with 0.2 ml of human plasma in the following outline: negative control (A), positive control (B), treatment with plasma 1 (C), treatment with plasma 2(D), and treatment with plasma 3 (E). Mice treated with human plasma showed an increase in longevity of $40.9{\pm}0.3$ (C), $20{\pm}9.0$ (D) and $35.6{\pm}9.3$ (E) days compared to the control group (B) which was $4.3{\pm}0.5$ days. The number of surviving mice and free of the parasite (blood smear and PCR negative) at the end of the experiment was 90%, 0%, and 60% for groups C, D, and E, respectively. The quantification of APOL1 was performed due to the large difference in the treatments that differed in the source plasma. In plasmas 1, 2, and 3 was detected the concentration of 194, 99, and 115 mg/dl of APOL1, respectively. However, we believe that this difference in the treatment efficiency is related to the level of APOL1 in plasmas.

Keywords

References

  1. Silva RAMS, Seidl A, Ramirez L, Davila AMR. Trypanosoma evansi e Trypanosoma vivax: biologia diagnostico e controle. Corumba. Embrapa Pantanal. 2002, p 166.
  2. Lun ZR, Desser SS. Is the broad range of hosts and geographical distribution of Trypanosoma evansi attributable to the loss of maxicircle kinetoplast DNA? Parasitol Today 1995; 11: 131-133. https://doi.org/10.1016/0169-4758(95)80129-4
  3. Hoare CA. The Trypanosomes of mammals: A zoological monograph. Oxford, UK. Blackwell Publ. Co. 1972, p 749.
  4. Kubiak GVL, Molfi A. Tripanosomiase equina (Mal das Cadeiras). Boletim n.33. Instituto de Biologia e Pesquisas Tecnologicas do Estado do Parana. Curitiba, Tip. Joao Haupt & Cia. Ltda. 1954, p 72.
  5. Joshi PP, Shegokar VR, Powar RM, Herder S, Katti R, Salkar HR, Dani VS, Bhargava A, Jannin J, Truc P. Human trypanosomosis caused by Trypanosoma evansi in India: The first case report. Am J Trop Med Hyg 2005; 73: 491-495.
  6. Shegokar VR, Powar RM, Joshi PP, Bhargava A, Dani VS, Katti R, Zare VR, Khanande VD, Jannin J, Truc P. Short report: Human trypanosomiasis caused by Trypanosoma evansi in a village in India: preliminary serologic survey of the local population. Am J Trop Med Hyg 2006; 75: 869-870.
  7. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homble F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005; 309: 469-472. https://doi.org/10.1126/science.1114566
  8. Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, Katti R, Jannin JG, Pays E. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N Engl J Med 2006; 355: 2752-2756. https://doi.org/10.1056/NEJMoa063265
  9. Otto MA, da Silva AS, Gressler LT, Farret MH, Tavares KC, Zanette RA, Miletti LC, Monteiro SG. Susceptibility of Trypanosoma evansi to human blood and plasma in infected mice. Vet Parasitol 2010; 168: 1-4. https://doi.org/10.1016/j.vetpar.2009.10.020
  10. Otto MA, da Silva AS, Gressler LT, Dall'Agnol LP, Bottam J, Zanette RA, Oliveira DC, Monteiro SG. Trypanosoma evansi: therapy with human plasma in infected rats. Comp Clin Pathol 2011; 20: 139-141. https://doi.org/10.1007/s00580-010-0968-7
  11. Colpo CB, Colpo ETB, Stainki DR, Monteiro SG. Infeccao Natural por Trypanosoma evansi em cao no Rio Grande do Sul. Ciencia Rural 2005; 35: 717-719. https://doi.org/10.1590/S0103-84782005000300038
  12. da Silva AS, Doyle RL, Monteiro SG. Metodo de contencao e confeccao de esfregaco sanguineo para pesquisa de hemoparasitas em ratos e camundongos. FZVA 2006; 13: 83-87.
  13. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Second edition. New York. Cold Spring Harbor Laboratory Press. 1989, p 300.
  14. Ventura RM, Takeda GF, Silva RA, Nunes VL, Buck GA, Teixeira MM. Genetic relatedness among Trypanosoma evansi stocks by random amplification of polymorphic DNA and evaluation of a synapomorphic DNA fragment for species-specific diagnosis. Int J Parasitol 2002; 32: 53-63. https://doi.org/10.1016/S0020-7519(01)00314-9
  15. Tuntasuvan D, Jarabrum W, Viseshakul N, Mohkaew K, Borisutsuwan S, Theeraphan A, Kongkanjana N. Chemotherapy of surra in horses and mules with diminazene aceturate. Vet Parasitol 2003; 110: 227-233. https://doi.org/10.1016/S0304-4017(02)00304-7
  16. da Silva AS, Tochetto C, Zanette RA, Pierezan F, Rissi DR, Santurio JM, Monteiro SG. Aceturato de diminazeno e dipropionato de imidocarb no controle de infeccao por Trypanosoma evansi em Rattus norvegicus infectados experimentalmente. Cienc Rural 2008; 38: 1357-1362. https://doi.org/10.1590/S0103-84782008000500025
  17. Da Silva AS, Andrade Neto OAS, Costa MM, Wolkmer P, Mazzanti CM, Santurio JM, Lopes STA, Monteiro SG. Tripanossomose em equinos na regiao sul do Brasil. Acta Sci Vet 2010; 38: 113-120.
  18. Jenings FW, Whitelaw DD, Urquhart GM. The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology 1977; 75: 143-153. https://doi.org/10.1017/S0031182000062284
  19. Spinosa HS, Gorniak SL, Bernardi MM. Farmacologia aplicada a medicina veterinaria. Rio de Janeiro. Guanabara koogan. 1999, p 946.
  20. Lai DH, Wang QP, Li Z, Luckins AG, Reid SA, Lun ZR. Investigations into human serum sensitivity expressed by stocks of Trypanosoma brucei evansi. Int J Parasitol 2010; 40: 705-710. https://doi.org/10.1016/j.ijpara.2009.11.009
  21. Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Perez-Morga D. The trypanolytic factor of human serum. Nat Rev Microbiol 2006; 4: 477-486. https://doi.org/10.1038/nrmicro1428
  22. Rifkin MR. Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci USA 1978: 75: 3450-3454. https://doi.org/10.1073/pnas.75.7.3450
  23. Hajduk SL, Moore DR, Vasudevacharya J, Siqueira H, Torri AF, Tytler EM, Esko JD. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J Biol Chem 1989; 264: 5210-5217.
  24. Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun 1999; 67: 1910-1916.

Cited by

  1. The effect of normal human serum on the mouse trypanosome Trypanosoma musculi in vitro and in vivo vol.184, pp.None, 2011, https://doi.org/10.1016/j.exppara.2017.12.005